Announcement • May 29
OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026 OptiBiotix Health Plc, Annual General Meeting, Jun 23, 2026. Location: the offices of marex, 155 bishopsgate, ec2m 3tq, london United Kingdom Reported Earnings • May 28
Full year 2025 earnings released: UK£0.038 loss per share (vs UK£0.018 loss in FY 2024) Full year 2025 results: UK£0.038 loss per share (further deteriorated from UK£0.018 loss in FY 2024). Revenue: UK£1.17m (up 34% from FY 2024). Net loss: UK£3.89m (loss widened 116% from FY 2024). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. New Risk • Apr 04
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£5.37m market cap, or US$7.09m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Announcement • Feb 25
OptiBiotix Health plc Announces Commencement of Clinical Study with Hull University Teaching Hospital Nhs Trust OptiBiotix Health plc announced the commencement of a clinical study with Hull University Teaching Hospital NHS Trust to determine the effect of taking WellBiome on cardiac surgery outcomes and potential NHS cost savings. A number of studies (Ardema 2019, Xia 2021) have suggested a decrease in microbial diversity and abundance post-surgery may increase hospital stays and that prebiotics like WellBiome, which increase microbial diversity and abundance and have systemic anti-inflammatory effects, may improve surgical outcomes. This double blind, placebo-controlled study of up to 60 patients is designed to evaluate the effect of six-week pre-operative supplementation on time spent in intensive care, length of hospital stay, and the incidence of post-operative complications. The study includes a cost savings analysis to identify any potential cost savings to the NHS and inform the future use of prebiotic like WellBiome in improving health outcomes and cost savings. WellBiome is a patented mineral-enriched prebiotic fibre complex developed in collaboration with leading UK Universities to enhance gut microbiome diversity greater than single prebiotic fibres alone. WellBiome has a number of European and USA on pack health claims including: Nourishes beneficial bacteria throughout the entire gut to improve gut health; Contributes to improved bone health by aiding the absorption of essential minerals; Contributes to normal muscle function, including heart muscle; Supports normal brain health function and memory; Contributes to normal psychological function; Supports cardiovascular health; Contributes to a reduction of tiredness and fatigue. New Risk • Jan 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 64% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Market cap is less than US$100m (UK£7.85m market cap, or US$10.5m). New Risk • Dec 08
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.49m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 64% per year over the past 5 years. Market cap is less than US$10m (UK£7.49m market cap, or US$9.97m). Minor Risk Revenue is less than US$5m (UK£1.2m revenue, or US$1.5m). Announcement • Nov 24
OptiBiotix Health Plc Provides Update on its SweetBiotix Product Range for New and Existing Investors OptiBiotix Health plc provided an overview and update on its SweetBiotix product range for new and existing investors. SweetBiotix®? are a portfolio of natural, sweet, high fibre, low-calorie products developed to replace sugar and sugar substitutes. They are produced using a patented technology developed by OptiBiotix which enzymatically modifies existing natural sweeteners like steviol glycosides and mogrosides and converts them into dietary fibres, providing sweetness with added nutritional and health benefits. SweetBiotix are trademarked and patented products protected by a significant intellectual property portfolio comprising over 25 patents with a number of recent additional filings. Patients must demonstrate novelty/uniqueness, inventiveness (i.e. no one else has invented it), and industry applicability confirming the uniqueness of SweetBiotix. SweetBiotix are unique as a sugar substitute as they have been developed to overcome health concerns, are high in fibre, and have prebiotic functionality providing nutritional and health benefits not present in existing products. This a market estimated to be worth $29.9 billion by 2029 (Markets and Markets: Oct 2024). What is the evidence that SweetBiotix are sweet and have health benefits SweetBiotix products have been tested by academic groups who have published five papers in peer reviewed journals providing an independent assessment of SweetBiotix's taste and health benefits. One publication on an early SweetBiotix product concluded ' This new ingredient could provide health benefits when evaluated in human studies by combining sweetness and prebiotic fiber functionality'. The Company has provided SweetBiotix samples under Material Transfer Agreements (MTA) to a number of partners, many of whom have specialist expertise in taste testing and sugar substitutes. This has led to a formal agreement with a USA partner and DSM Firmenich, a $12 billion ingredients supplier, and several food and beverage companies supporting SweetBiotix development with a view to the use of SweetBiotix in their products. This changes the positioning with sugar producers who have previously seen SweetBiotix as a competitor, to a potential partner, by offering a unique, patented process which can utilise and modify commoditised sucrose into higher valued SweetBiotix products. Importantly, whilst there is a material change in the enzymatic process there is no change to the resulting SweetBiotix product other than higher yields which significantly increases the purity (90%) of the final product. The Company believes that most of the process changes are covered within its existing patent portfolio but has extended its filings on the enzyme use and composition given the uniqueness and commercial potential of their properties. Next steps The Company is producing quantities of SweetBiotix for its development, manufacturing, and application partners and sharing the new enzymatic process with DSM Firmenich, US partner, and major sugar producers given its potential to valorise sugar. The Company continues to receive an annual milestone of PS100k from its US partner related to work on Mogrosides with total received to end of 2024 of PS550k. Milestone payments are rarely seen in the food, beverage and supplement industry, even less so prior to commercial launch and should give investors' confidence in the value attributed to this technology by industry. Subject to any partner constraints, the Company hopes to be in a position to demonstrate a range of SweetBiotix products to investors in first first half of 2026. Subject to any partner restrictions, the Company hopes to be In addition to any partner constraints, the company hopes to be in a positions to demonstrate a range of Sweet Biotix products to investors in H1 2026. The Company has made a breakthrough in improving the manufacturing process of its SweetBiotix products. By using a new enzyme, rather than an enzyme extract, the Company is able to achieve substantially higher yields of a purer, more concentrated, better tasting product with lower ingredient and production costs. These are significant benefits when producing at large scale. This new enzyme works on both mogrosides and stevia glycosides allowing the generation of multiple SweetBiotix products to multiple SweetBiotix products. Reported Earnings • Sep 17
First half 2025 earnings released: UK£0.011 loss per share (vs UK£0.03 loss in 1H 2024) First half 2025 results: UK£0.011 loss per share (improved from UK£0.03 loss in 1H 2024). Revenue: UK£557.0k (up 102% from 1H 2024). Net loss: UK£1.18m (loss narrowed 58% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Announcement • Sep 17
OptiBiotix Health plc Provides Sales Guidance for the Second Half of the Year 2025 OptiBiotix Health Plc provided sales guidance for the second half of the year 2025. For the period, the company anticipates continued strong sales growth. Announcement • Aug 16
OptiBiotix Health plc Announces Launch of SlimBiome in Leading US brand OptiBiotix Health plc announced the launch of a product containing its award-winning appetite reducing SlimBiome®? in Hydroxycut, which markets itself as the No. 1 selling weight loss supplement brand in the United States of America ("USA"). This announcement confirms the launch of the first product under the brand name 'Hydroxycut hunger Control', and follows on from the first order announcement on 15 April 2025. The product is sold through online outlets and retail outlets such as Walmart, Kroger, Target, GNC, Kmart, Albertsons, CVS Pharmacies and more. The brand has high customer awareness and in recent years has become increasingly known for its science backed products. The introduction of SlimBiome®?, with its scientifically substantiated health claims of hunger control, helps to differentiate these products from other weight management products on the market. This news is significant for the Company as it represents the inclusion of SlimBiome®? in the products of one of the USA's most popular weight management brands which has led to orders totaling just under five metric tonnes for SlimBiome®? in 2025. The Board believes that the opportunity has potential for future development and will provide further updates in due course. Reported Earnings • Jun 30
Full year 2024 earnings released: UK£0.018 loss per share (vs UK£0.023 loss in FY 2023) Full year 2024 results: UK£0.018 loss per share (improved from UK£0.023 loss in FY 2023). Revenue: UK£870.0k (up 35% from FY 2023). Net loss: UK£1.81m (loss narrowed 12% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance. Announcement • Jun 30
OptiBiotix Health Plc, Annual General Meeting, Aug 06, 2025 OptiBiotix Health Plc, Annual General Meeting, Aug 06, 2025. Location: the offices of walbrook pr, 75 king william st, ec4n 7be, london United Kingdom Announcement • Jun 11
OptiBiotix Health plc Announces the Publication of New Peer-Reviewed Study on SlimBiome®? in the European Journal of Nutrition OptiBiotix Health plc announced the publication of a new peer-reviewed study on SlimBiome®? in the European Journal of Nutrition. The European Journal of Nutrition is a peer reviewed, international journal that has a high impact factor with its articles widely cited and influential in its field. The double-blind placebo-controlled study, led by Adele Costabile, Professor of Clinical Nutrition and the Microbiome at the University of Roehampton, found a single 3g dose of SlimBiome significantly reduced insulin levels, hunger, and the desire to eat whilst increasing the feeling of fullness. These are key factors in appetite regulation and the study conclusion highlights the potential of SlimBiome®? as a non-pharmaceutical approach to weight management. These findings on the impact of a single dose of SlimBiome®? are consistent with other published studies, consumer studies, and customer feedback which have shown SlimBiome®? reduces hunger and food cravings leading to users both reducing the amount of food and the type of food they eat, leading to more sustainable weight management. The study was carried out to support health claims for appetite regulation and hunger control in products of one of the USA's leading weight management brands. Scientifically substantiated health claims help to differentiate SlimBiome®? from other products on the market. OptiBiotix now has acute and long-term studies in healthy, overweight, and obese individuals which have allowed the Company to make on pack health claims in Europe, Australia/New Zealand, India, Asia, Canada, and the USA leading to agreements and multiple product launches with major international and national companies and brands (e.g Morepen, Muscletech, Myprotein). In the changing landscape of this market, brought about by the anti-obesity drugs, traditional approaches to weight management are being replaced by science backed products which provide functional benefits such as reduced hunger and desire to eat. SlimBiome®? meets this developing trend. The study adds further evidence to demonstrate the efficacy of SlimBiome®? in reducing hunger and food cravings leading the amount and type of food people eat. Whilst the anti-obesity drugs have strong risk-benefits in the 16% of the world adult population who are obese, they may not be the best choice for the 43% who are overweight. SlimBiome®? represents a natural alternative, particularly for overweight individuals, and has been widely used with no reported adverse side effects". Announcement • May 22
OptiBiotix Health plc Announces Launch of SlimBiome Products with NASDAQ Listed Partner, Natural Health Trends Corp OptiBiotix Health plc announced the launch of products containing SlimBiome® with a NASDAQ listed partner, Natural Health Trends Corp. NHT is an international direct selling and ecommerce company operating through its subsidiaries throughout Asia, the Americas, and Europe. The Company markets premium quality products under the NHT global brand. The product, which was produced and shipped in final product format by OptiBiotix is a Tomato Soup formulation, TwinSlim Tomato Soup, developed specifically for NHT and its global markets. The product has been launched in Hong Kong for the Chinese market with the product shipped for launch in the USA in the upcoming weeks. OptiBiotix has been involved in presentations to NHT's Asian distributors and filming videos explaining the science and benefits of SlimBiome® for both the Asian and USA markets. This is the second USA partner launching SlimBiome®? products in the last few months, with a third, one of the USA's leading weight management brands, expected to launch in the near future. This is all part of the Company's strategy to develop and market clinically proven and patented products with functional benefits (for SlimBiome®?: reduce hunger and food cravings) and grow business in the high growth markets of Asia, particularly India, and the large USA market, through a mix of ingredient and finished products sold by brand owners, specialised distributors and e-commerce channels. OptiBiotix is now beginning to see returns from the investments made in clinical studies, intellectual property, and more recently supporting partners in their marketing at a time when the anti-obesity drugs have enhanced consumer awareness of the benefits of appetite suppression in weight management. The focus now is on increasing the number of large partners and delivering regular repeat orders to reach group profitability. New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 35% per year over the past 5 years. Revenue is less than US$1m (UK£569k revenue, or US$753k). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (UK£15.7m market cap, or US$20.8m). Announcement • Feb 18
OptiBiotix Health Plc Announces Launch of Daily Nouri FeelFull Product in America OptiBiotix Health Plc announced the launch of FeelFull, containing SlimBiome®, by Daily Nouri ("Nouri") in the United States of America (USA). Daily Nouri is a well-known brand in the USA known for its science-backed, clinically supported probiotic and prebiotic solutions which impact on gut health.Nouri sell their products in their online store, on Amazon, and in stores of some of the larger retailers in the USA such as Walmart and Albertsons. FeelFull is a prebiotic lemonade drink containing SlimBiome® formulated by Nouri which has been created "to helpconsumers regulate appetite, curb cravings, and support metabolic health by increasing viscosity in the stomach, slowing gastric emptying, and stabilising blood sugar levels to create a feeling of fullness and help satiate overall desire for food intake.". The lemonade is a powdered drink in portable stick packs which can be mixed with water with 'on pack' health claims which state daily use supports 'reduced appetite and cravings' and a 'feeling of fullness' derived from OptiBiotix's multiple clinical studies. 'On pack' health claims are important in differentiating products in the weight management market and are an area of high consumer interest since the launch of the appetite reducing anti-obesity drugs. Nouri forecast a requirement for ten metric tons of SlimBiome® in year one. Announcement • Dec 03
OptiBiotix Health Launches Dr. Morepen Lightlife in India OptiBiotix Health plc announced the upcoming launch of multiple SlimBiome® containing products under Dr. Morepen's ("Morepen") newly developed LightLife brand in India. This is being supported by a £1.5million+ marketing investment and follows on from the partnership agreement signed with Morepen in March 2024 for the sale of SlimBiome® containing products in India. Morepen's launch will include five flavoured variants of SlimBiome® containing sachets and a meal replacement with further products to be added during First Quarter 2025 and throughout the year. The LightLife brand will be positioned as India's first 360° weight management plan. As part of this launch, Morepen will be providing personalised nutrition plans, expert nutrition and expert fitness counselling which will be available to LightLife consumers via a newly developed app. This has been designed to offer support to consumers throughout their weight loss journey by offering free app videos and content with specifically tailored plans for individuals. This is the first time OptiBiotix has co-invested in marketing with a partner on this scale and includes a significant and comprehensive marketing plan and budget of £1.5m+. This will include significant use of influencers, PR, and numerous digital marketing activities and strategies with the aim of rapidly gaining a significant market share. The products will be sold on Morepen's website, across all major online ecommerce platforms in India and will be available in 5,000+ pharmacies across all key cities in India within the first year of launch. Obesity is a significant and rapidly growing issue across India, expected to worsen as India's middle class continues to grow. According to the Indian National Family Health Survey (NFHS-5) 2019-2021, around 23% of Indian men and 24% of Indian women are overweight or obese, leading to cardiovascular, diabetes, respiratory and knee joint health issues. Morepen estimate the target market for LightLife in India to be approximately 197 million adults. Revenues will be both generated through raw material sales of SlimBiome® to the contract manufacturer KAG Industries (RNS: 30 April 2024) and as a second larger revenue stream for the finished product sold direct to Morepen. Announcement • Oct 24
OptiBiotix Health Plc Announces Finance Director Changes OptiBiotix Health plc announced that Graham Myers, Finance Director of the company, has notified the company that he will step down from the Board on 30 November 2024. David Blain will join the company as acting Finance Director on 1 November 2024. Mr. Blain's appointment to the Board of the company will be subject to normal regulatory due diligence. David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr. Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd. Announcement • Oct 10
OptiBiotix Health Plc Announces Further Positive Study Results on SlimBiome OptiBiotix Health plc announced further positive study results. The Company has completed a fourth human study on SlimBiome®, which followed recommended industry guidelines and was designed to investigate the acute impact of a single dose of SlimBiome® in the presence of 50g sugar (12 teaspoons) on 20 overweight volunteers on their glycaemic response, hunger, and cravings. Feelings of hunger, fullness, desire to eat, and amount of food desired were assessed at 0, 75 and 150min using the visual analogue scale, a validated questionnaire used in nutrition research to assess appetite and food intake. The researchers at the Brunel University of London reported results showing significant impact on multiple parameters important to appetite and hunger regulation including: - A statistically significant reduction (26.85%) in hunger (p=0.007) with the intake of SlimBiome®. Participants were approximately seven times less hungry when taking SlimBiome® compared to sugar. A statistically significant increase (46.9%) in fullness compared to baseline (p=0.009). Participants were approximately two times fuller when taking SlimBiome® compared to sugar. No safety, compliance, or tolerance issues were reported by volunteers. The results of this study are aligned with the Company's earlier study on the acute impact of SlimBiome® in healthy weight volunteers and provide further evidence of the ability of a single dose of SlimBiome® to moderate the impact of the ingestion of a large amount of sugar on appetite related parameters and support fullness. Researchers at the University of Nottingham report that in stomach simulation laboratory experiments, SlimBiome resulted in a six-fold increase in viscosity when taken with sugar and in a 9.6-fold increase in viscosity when taken with a meal replacement which is related with the ability of SlimBiome to support the feeling of fullness and reduce hunger.
The results are consistent with consumer feedback and customer product reviews who report feeling less hungry leading to reduced snacking and lower food intake leading to an average weight loss of 1.2kg per week.
These findings show SlimBiome® can have a role as a functional ingredient by itself as in SlimBiome Medical®, in meal replacements as in GoFigure®, or as part of a healthy snack in controlling hunger and desire to eat as part of a calorie controlled diet. Reported Earnings • Oct 01
First half 2024 earnings released: UK£0.03 loss per share (vs UK£0.021 loss in 1H 2023) First half 2024 results: UK£0.03 loss per share (further deteriorated from UK£0.021 loss in 1H 2023). Net loss: UK£2.79m (loss widened 51% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 75 percentage points per year, which is a significant difference in performance. Reported Earnings • Jun 30
Full year 2023 earnings released Full year 2023 results: Net income: (down UK£2.59m from profit in FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance. New Risk • Jun 30
New major risk - Revenue and earnings growth Earnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 16% per year over the past 5 years. Revenue is less than US$1m (UK£667k revenue, or US$843k). Minor Risks Shareholders have been diluted in the past year (7.4% increase in shares outstanding). Market cap is less than US$100m (UK£15.7m market cap, or US$19.8m). Announcement • Jun 29
OptiBiotix Health Plc, Annual General Meeting, Aug 08, 2024 OptiBiotix Health Plc, Annual General Meeting, Aug 08, 2024. Location: the offices of peterhouse capital limited, 3rd floor, 80 cheapside, ec2v 6ee, london United Kingdom Announcement • Jun 21
OptiBiotix Health Plc Announces Slimbiome Study Results OptiBiotix Health plc notes the latest results from the human studies carried out at Roehampton University, London on OptiBiotix's SlimBiome. Study outcomes, awaiting publication, suggested SlimBiome® intake had a major impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness within 15 minutes, for over two hours after consumption. This is one of four studies which have consistently shown SlimBiome® reduces hunger and food cravings leading to users both reducing the amount of food and changing the type of food they eat, to less calorie intense food leading to sustainable weight management. This suggests that SlimBiome® can be used as a natural alternative to the current anti-obesity drugs on the market. These findings on the acute impact of one dose of SlimBiome® are consistent with those of a previous first study, also carried out by Professor Adele Costabile, published in the Journal of Functional Foods (November 2020) which showed that volunteers taking SlimBiome® for four weeks experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods. SlimBiome® is availableherein sachets as SlimBiome Medical®/SlimBiome X3 or in meal replacements, bars, gummies, and soups/porridges and is increasingly being used by major sports nutrition brands to support lean body development. The latest results from human studies reinforce findings that a mineral enriched prebiotic fibre complex can help reduce hunger by 27% and support the feeling of fullness by 35% offering a rapid and natural solution for those seeking support in weight management. The latest results from a study conducted by Professor Adele Costabile at the University of Roehampton using Optibitix's SlimBiome® saw 20 volunteers given 50g (12 teaspoons) of sugar with and without SlimBiome®. Study outcomes, awaiting publication, suggested SlimBiome® intake had a significant impact on insulin response combined with significantly lower feelings of hunger, a lower desire to eat, and significantly higher levels of fullness for over two hours after consumption. These findings on the acute impact of one dose of SlimBiome are consistent with those of a previous first study, also carried out by Professor Adele and her team, published in the Journal of Functional Foods (November 2020) which showed that taking SlimBiome® for four weeks volunteers experienced a 21% reduction in cravings for sweet foods and a 30% reduction in cravings for savoury foods. Overall, 90% of volunteers lost weight and all volunteers reported a reduction in waist and hip circumference and lost body fat. In addition, volunteers improved their mood by 26%, suggesting they were losing weight without feeling hungry or craving for food making it more sustainable. The results also showed a significant change in volunteers gut microbiome with a statistically significant increase in microbes associated with a lean body. These studies suggest that a natural ingredient like SlimBiome®, which was tolerated well in all studies, may offer a natural approach to managing hunger and food cravings to support weight management. Whilst using different mechanisms of action, SlimBiome® and anti-obesity drugs work in a similar way by regulating insulin response and promoting the feelings of fullness by slowing down stomach emptying. New Risk • Apr 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£689k revenue, or US$858k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (7.4% increase in shares outstanding). Market cap is less than US$100m (UK£18.9m market cap, or US$23.5m). New Risk • Mar 25
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£689k revenue, or US$871k). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (7.4% increase in shares outstanding). Market cap is less than US$100m (UK£20.6m market cap, or US$26.0m). Announcement • Jan 15
OptiBiotix Health PlcAnnounces Launch of LeanBiome in Muscletech OptiBiotix Health plc announced the forthcoming launch of LeanBiome in Muscletech,one of the leading sports nutrition brands in the industry and backed by America's No. 1 selling sports supplement company. The product is currently being advertised on social media by the Company's partner ahead of online and instore launches with multiple retailers in Sweden, France, Poland, Germany, the Netherlands, Greece and the UK. Muscletech®is known as a leading brand in the science nutrition space recognised for its research with scientific experts to identify and utilise science backed ingredients in their products to bring unique benefits to athletes and fitness enthusiasts around the world.LeanBiome® will be incorporated in Muscletech Nitro Tech Ripped range, a premium protein powder designed to support athletes who want to lose fat and build lean muscle and willbe launched in Europe and the United Kingdom across multiple e-commerce sites and distribution channels. LeanBiome®is a scientifically formulated sports nutrition ingredient which has been developed by OptiBiotix to support athletes seeking to increase lean muscle mass and to change their body composition. LeanBiome®contains a patented combination of fibres, prebiotics and minerals developed to increase the microbiome diversity of athletes on a high protein diet. A diverse microbiome is important in harvesting essential nutrients from the diet and has been linked to improved health and wellbeing and increased resilience to disease. Many researchers now believe that a diverse microbiome is an essential factor in achieving physical fitness, which was previously thought to be achievable solely through a healthy diet and regular exercise. This is supported by the growing scientific evidence of a link between the microbiome and athletic performance which suggest that optimizing an athletes gut microbiome could improve and athletes stamina, lower inflammation, and support physical fitness (Frontiers | Editorial: Nutrition to support gut health and the microbiome in athletes. Announcement • Dec 04
Optibiotix Health plc Appoints Graham Myers as Finance Director OptiBiotix Health Plc announces that Graham Myers has been appointed as Finance Director of the Company as of 1 December 2023. Graham is a member of the Institute of Chartered Accountants in England & Wales and has extensive financial and commercial experience in a number of private and public companies, including being a member of the Executive Committee at Croda International Plc, where he worked for almost 30 years. Graham brings extensive experience in optimising financial controls, managing budgets, building profitable businesses and mergers & acquisitions. Graham is currently Chair of Croda Pension Trustees Limited, the sole trustee of Croda's £800m UK pension scheme. Graham's appointment to this part-time role will see him work closely with the OptiBiotix team to support thefocus on driving each business unit and the Group to profitability. Reported Earnings • Sep 29
First half 2023 earnings released: UK£0.021 loss per share (vs UK£0.16 profit in 1H 2022) First half 2023 results: UK£0.021 loss per share (down from UK£0.16 profit in 1H 2022). Net loss: UK£1.85m (down 113% from profit in 1H 2022). Announcement • Jul 27
OptiBiotix Health plc Announces Cessation of Directors Further to the announcement of 28 June 2023, OptiBiotix Health Plc confirms that Non-executive Directors Stephen Hammond and Chris Brinsmead have not put themselves for re-election as Directors and have therefore, with immediate effect, ceased to be Directors of the Company. Announcement • Jul 21
OptiBiotix Health plc Provides an Overview of its SweetBiotix Product Range OptiBiotix Health plc provided an overview of its SweetBiotix product range in the light of recent news interest in sweeteners. Meeting the market need: OptiBiotix has developed a portfolio of novel, patented, zero or low calorie sweet dietary fibres, called SweetBiotix. They are unique in that they do not have the health concerns associated with sugar, corn syrup, or sweeteners and importantly, from a health and nutritional labelling perspective, are classified as dietary fibres. In addition to the benefits of increasing fibre intake, SweetBiotix fibres have been shown to have a prebiotic effect by increasing the production of short chain fatty acids. SCFAs are widely known for their importance in gut health, immunity and how energy is metabolised in the body and are one of the main ways in which the gut microbiome contributes to better health. This creates a clear differentiator to other products on the market and an opportunity to replace unhealthy sugars with healthy fibres in a range of food and beverage products and as an ingredient in its own right. The SweetBiotix portfolio contains a range of products which human studies have shown have high (240X the sweetness of sugar) to moderate levels of sweetness (3X) to meet the needs of a wide range of application including fizzy drinks, snacks, bakery products, dairy products and cereals. As a general guide, the high-level sweet products could be considered a replacement for existing sweeteners whilst the moderate level sweetness products as bulk sugar replacement products. The strategy is designed to create multiple opportunities which offer added value and use for a wide range of product applications. Whist taking longer, this reduces the commercial risk which would exist with a single product approach whilst increasing the scale of the opportunity. Product developments OptiBiotix'sproducts are differentiated from other natural sweeteners and sugar substitutes on the market in that they have been developed: To be classified on packaging as dietary fibres providing no contribution to sugar intake and enhancing product nutritional labels. Have a low glycemic index (reducing the risk of developing diabetes). Enhance the gut microbiome providing additional potential health benefits. Have intense sweetness (High Intensity Sweeteners) or sweetness similar to sugar (depending on product). Current position: Both product types are at the end stage of manufacturing scale up with ongoing testing of samples with both partners. This is a complex and rigorous process. Typically, global partners with established brands require confirmation of a robust supply chain for all ingredients (ethically and responsibly sourced) from two different suppliers, low waste streams, humans studies/taste tests and structural and functional analysis on liquid and freeze-dried products from three different production runs to show there is no batch to batch variability. In addition, most require two year shelf life of SweetBiotix as an ingredient and in their final products with no observable effect on appearance, taste, or texture or functionality. New Risk • Jun 29
New major risk - Revenue size The company makes less than US$1m in revenue. Total revenue: UK£457k (US$577k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks High level of non-cash earnings (29% accrual ratio). Revenue is less than US$1m (UK£457k revenue, or US$577k). Market cap is less than US$10m (UK£5.47m market cap, or US$6.90m). Minor Risk Shareholders have been diluted in the past year (3.5% increase in shares outstanding). Reported Earnings • Jun 29
Full year 2022 earnings released: EPS: UK£0.029 (vs UK£0.071 in FY 2021) Full year 2022 results: EPS: UK£0.029 (down from UK£0.071 in FY 2021). Net income: UK£2.59m (down 59% from FY 2021). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Announcement • Jun 28
OptiBiotix Health Plc, Annual General Meeting, Jul 26, 2023 OptiBiotix Health Plc, Annual General Meeting, Jul 26, 2023, at 10:00 Coordinated Universal Time. Location: Walbrook PR Ltd, 75 King William Street London, United Kingdom Agenda: To consider re-election as directors of the Company and will therefore cease to be directors following the conclusion of the AGM. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Non-Executive Director Stephen Hammond was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Sep 28
First half 2022 earnings released: EPS: UK£0.042 (vs UK£0.16 in 1H 2021) First half 2022 results: EPS: UK£0.042 (down from UK£0.16 in 1H 2021). Net income: UK£3.66m (down 74% from 1H 2021). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 29
Full year 2021 earnings: EPS misses analyst expectations Full year 2021 results: EPS: UK£0.072 (up from UK£0.067 in FY 2020). Net income: UK£6.26m (up 7.9% from FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.7%. Over the next year, revenue is forecast to grow 37%, compared to a 160% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 76% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Non-Executive Director Stephen Hammond was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 11
Full year 2020 earnings released: EPS UK£0.067 (vs UK£0.026 loss in FY 2019) Full year 2020 results: Net income: UK£5.80m (up UK£7.99m from FY 2019). Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 18
Full year 2020 earnings released: EPS UK£0.067 (vs UK£0.023 loss in FY 2019) Full year 2020 results: Net income: UK£5.80m (up UK£7.76m from FY 2019). Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 23
New 90-day high: UK£0.66 The company is up 26% from its price of UK£0.52 on 23 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 15% over the same period. Is New 90 Day High Low • Jan 07
New 90-day high: UK£0.66 The company is up 10.0% from its price of UK£0.59 on 09 October 2020. The British market is up 14% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Biotechs industry, which is also up 10.0% over the same period. Announcement • Dec 11
OptiBiotix Health Plc Announces Board Changes OptiBiotix Health Plc announced that it intends to appoint Christopher Brinsmead CBE as a Director of the Company, subject to the completion of regulatory due diligence being carried out by the Company's Nomad. Chris will replace Peter Wennstrom as a director of the Company on confirmation of his appointment. Peter will continue in an advisory capacity for the Company following his resignation from the Board. Is New 90 Day High Low • Oct 30
New 90-day low: UK£0.49 The company is down 6.0% from its price of UK£0.52 on 31 July 2020. The British market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. Announcement • Oct 14
Optibiotix Health plc Announces Launch of Weight Management Products in Australia and New Zealand OptiBiotix Health plc announced the launch of meal replacement shakes and bars containing OptiBiotix's OptiBiome® proprietary weight management technology under the Optislim® brand with Woolworths, ChemistWarehouse and on OptiPharm Pty Ltd's (OptiPharm) online store in Australia and New Zealand. These simultaneous launches build on a licence agreement entered into in March 2020 granting OptiPharm exclusive use of the OptiBiome® trademark in Australia, parts of Asia, New Zealand, Middle East, the Gulf States and North America. Announcement • Oct 08
OptiBiotix Health plc Announces Appointment of Aneta Zlotkowskaas as Head of Quality & Operations OptiBiotix Health plc announced the appointment of Aneta Zlotkowskaas as Head of Quality & Operations. Aneta joins OptiBiotix from a position as Lead Development Manager at Tesco Plc. Prior to working for Tesco, Aneta was a Quality Assurance and Purchasing Manager at Cornelius Group Plc where she has also held the positions of Senior Supply Chain Executive and Supply Chain Manager. Is New 90 Day High Low • Oct 05
New 90-day high: UK£0.63 The company is up 29% from its price of UK£0.49 on 07 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period. Announcement • Oct 05
OptiBiotix Health Plc Enters into Exclusive Distribution Agreement with United Italian Trading Corporation (Pte) Ltd OptiBiotix Health plc announced it has entered into an exclusive distribution agreement for SlimBiome® Medical with United Italian Trading Corporation (Pte) Ltd. The agreement grants UITC exclusive rights to distribute OptiBiotix's SlimBiome® Medical proprietary weight management product in Singapore. Announcement • Sep 22
OptiBiotix Health plc Announces Non-Exclusive License Agreement with HiLife Vitamins for Slimbiome Medical in the USA OptiBiotix Health plc announced it has entered in to a non-exclusive license agreement for SlimBiome Medical with HiLife Vitamins & Herbs Co Inc. ("HiLife"). The agreement grants HiLife non-exclusive rights to commercialise OptiBiotix's SlimBiome® Medical proprietary weight management product in the USA. The signing of this agreement was subject to the placing of a trial order and a six month period after which both parties will discuss the terms of the agreement to explore online exclusivity for the USA. These discussions will follow a review of sales performance over the period. Any subsequent exclusivity agreed will be linked to minimum order quantities. Discussions to explore the manufacturing of SlimBiome® Medical locally in the USA will also take place with the aim of reducing logistical and import costs as volumes increase. This is another strategic step by OptiBiotix to commercialise its award-winning technology on an international stage in a major market. With the Company exploring listings in international markets, increasing global brand exposure both as an ingredient and as a finished product in retailers and online enhance the awareness of OptiBiotix's scientific and commercially validated technologies. 
